In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...

The FDA has approved semaglutide for treating MASH, a significant advancement in liver disease management. Semaglutide, ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity: San Diego Wednesday, August 20, ...

Patients with local or regional cutaneous squamous cell carcinoma are randomly assigned to receive cemiplimab or placebo post ...

One promising option is turmeric, a bright yellow spice commonly used in cooking. Its active compound, curcumin, has shown ...

The participants will receive either 100 mg of verekitug every 12 weeks, 400 mg every 24 weeks, or a placebo, throughout 60 ...

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...

Viking Therapeutics (VKTX) stock drops even as a mid-stage trial for its oral weight loss drug VK2735 succeeds. Novo (NVO) ...

ESK-001, a novel therapy for moderate to severe plaque psoriasis, had acceptable safety and efficacy outcomes at 12 weeks of treatment.

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...